Abstract
Hydroxyproline excretion in the urine was measured in five pituitary dwarfs during a 4-month period of treatment with 10 IU/week of growth hormone and during 4 months following treatment, in order to assess its value as an index of therapeutic response.The excretion of hydroxyproline was found to be within normal limits (26-57 mg/ 24 h/m<sup>2</sup>) on control days, and this excretion presented a gradual increase in the last 2 months of treatment; this was, however, not of statistical significance. After cessation of treatment, hydroxyproline levels returned to pretreatment values. The clinical effect was significant in all patients, who gained 2-5 cm within the 4 months of treatment, as compared to an anual increase of 1-3 cm during the pretreatment year. The above results suggest that hydroxyproline excretion cannot be considered as a reliable parameter of the therapeutic response of pituitary dwarfs to chronic growth hormone treatment with the established doses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
